Quality of care in patients with bladder cancer
Open Access
- 5 August 2011
- Vol. 118 (5), 1412-1421
- https://doi.org/10.1002/cncr.26402
Abstract
BACKGROUND: Although there is level I evidence demonstrating the superiority of intravesical therapy in patients with bladder cancer, surveillance strategies are primarily founded on expert opinion. The authors examined compliance with surveillance and treatment strategies and the pursuant impact on survival in patients with high‐grade disease. METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)‐Medicare data, the authors identified subjects with a diagnosis of high‐grade, non–muscle‐invasive disease between 1992 and 2002 who survived 2 years and did not undergo definitive treatment during that time. Nonlinear mixed‐effects regression analyses was used to examine compliance with surveillance and treatment strategies. After adjusting for confounders using a propensity score‐weighted approach, the authors determined whether individual and comprehensive strategies during the initial 2 years after diagnosis were associated with survival after 2 years. RESULTS: Of 4790 subjects, only 1 received all the recommended measures. Although mean utilization for most measures significantly increased after 1997, only compliance with an induction course of bacillus Calmette‐Guerin (BCG) increased (13% to 20%; P < .001). On multivariate analysis, compliance with ≥ 4 cystoscopies, ≥ 4 cytologies, and BCG instillation was found to be lower among octogenarians and higher among those with undifferentiated, Tis, and T1 tumors, and among those individuals diagnosed after 1997. Subjects compliant with these measures had a lower hazard of mortality (hazard ratio, 0.41; 95% confidence interval, 0.18‐0.93) than those who received < 4 cystoscopies, < 4 cytologies, and no BCG. CONCLUSION: There was a statistically significant survival advantage found among those who received at least half of the recommended care. Improving compliance with these process‐of‐care measures via systematic quality improvement initiatives serves as the primary target to meliorate bladder cancer care. Cancer 2012;. © 2011 American Cancer Society.Keywords
This publication has 60 references indexed in Scilit:
- Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparumCurrent Opinion in Infectious Diseases, 2011
- Patterns of care for early stage bladder cancerCancer, 2010
- Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?Cancer, 2009
- Provider Treatment Intensity and Outcomes for Patients With Early-Stage Bladder CancerJNCI Journal of the National Cancer Institute, 2009
- Evidence of Artemisinin-Resistant Malaria in Western CambodiaThe New England Journal of Medicine, 2008
- Predictors of Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Results From the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care ProjectJournal of Urology, 2008
- Comparison of a SYBR Green I-Based Assay with a Histidine-Rich Protein II Enzyme-Linked Immunosorbent Assay for In Vitro Antimalarial Drug Efficacy Testing and Application to Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2007
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Human Malaria Parasites in Continuous CultureScience, 1976